The present invention is related to methods for lowering peroxide levels in sucrose acetate isobutyrate formulations and to composition used in and formed by such methods.

Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

The present invention relates to novel pharmaceutical combinations and compositions comprising sucralfate and magnesium alginate, a process for their preparation and the use of said compositions in therapy, in particular for the treatment and/or prevention of disorders of the upper gastro-intestinal tract.

The present invention relates to novel pharmaceutical combinations and compositions comprising sucralfate and magnesium alginate, a process for their preparation and the use of said compositions in therapy, in particular for the treatment and/or prevention of disorders of the upper gastro-intestinal tract.

The present invention relates to novel pharmaceutical combinations and compositions comprising sucralfate and magnesium alginate, a process for their preparation and the use of said compositions in therapy, in particular for the treatment and/or prevention of disorders of the upper gastro-intestinal tract.

The present invention relates to a botulinum toxin pharmaceutical composition comprising tannic acid as an active ingredient. The botulinum toxin pharmaceutical composition comprising tannic acid provided in one aspect of the present invention improves the activity of the botulinum neurotoxin itself, allows the botulinum neurotoxin to stay in the injected place, and prevents the botulinum neurotoxin from spreading to the blood due to the properties of tannic acid. Therefore, the composition of the present invention has an effect of minimizing the side effects of the conventional Botox caused by the spread of the botulinum neurotoxin.

The present invention relates to a botulinum toxin pharmaceutical composition comprising tannic acid as an active ingredient. The botulinum toxin pharmaceutical composition comprising tannic acid provided in one aspect of the present invention improves the activity of the botulinum neurotoxin itself, allows the botulinum neurotoxin to stay in the injected place, and prevents the botulinum neurotoxin from spreading to the blood due to the properties of tannic acid. Therefore, the composition of the present invention has an effect of minimizing the side effects of the conventional Botox caused by the spread of the botulinum neurotoxin.

Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt % di-complex and a boric acid content of less than 15 wt %, and more typically less than 5 wt %. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components.

Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt % di-complex and a boric acid content of less than 15 wt %, and more typically less than 5 wt %. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components.